From $30M launch round to $400M buyout deal — with $250M upfront — in 10 short months

F-Prime’s Ben Auspitz has turned a modest investment in his newly launched biotech Modis Therapeutics into a quick score on the M&A side. And the deal comes with some lessons on the speed rare disease biotechs can move these days, as well as the value they can create in short order.